Goubau et al., 1992 - Google Patents
Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccineGoubau et al., 1992
- Document ID
- 16056599581229191023
- Author
- Goubau P
- Van Gerven V
- Safary A
- Delem A
- Knops J
- D'Hondt E
- André F
- Desmyter J
- Publication year
- Publication venue
- Vaccine
External Links
Snippet
A randomized double-blind comparison of five killed hepatitis A vaccine preparations was carried out with eligible medical student and staff volunteers. Vaccines were prepared in MRC-5 cells and formalin-inactivated. Three monthly injections of 1 ml in the deltoid muscle …
- 230000000694 effects 0 title abstract description 6
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andre et al. | Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings | |
| Andre | Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine | |
| Wiedermann et al. | Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers | |
| Zajac et al. | Overview of clinical studies with hepatitis B vaccine made by recombinant DNA | |
| Nothdurft et al. | A new accelerated vaccination schedule for rapid protection against hepatitis A and B | |
| Burlington et al. | Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus | |
| Nalin et al. | Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview | |
| Horng et al. | Safety and immunogenicity of hepatitis A vaccine in healthy children | |
| Moriniere et al. | Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine | |
| Bruguera et al. | Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in young adults | |
| Goubau et al. | Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine | |
| Lemon et al. | Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin | |
| Troisi et al. | Immunization of seronegative infants with hepatitis A vaccine (HAVRIX®; SKB): a comparative study of two dosing schedules | |
| Levie et al. | Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12–15 years | |
| Marine et al. | Reactions and serologic responses in young children and infants after administration of inactivated monovalent influenza A vaccine | |
| Faridi et al. | Immunogenicity and safety of live attenuated hepatitis A vaccine: a multicentric study | |
| Burgess et al. | Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study | |
| Berger et al. | Time course of hepatitis A antibody production after active, passive and active/passive immunisation: the results are highly dependent on the antibody test system used | |
| Just et al. | Reactogenicity and immunogenicity of inactivated hepatitis A vaccines | |
| Tichmann et al. | Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination | |
| Victor et al. | Hepatitis A vaccine. A new convenient single-dose schedule with booster when long-term immunization is warranted | |
| Karzon et al. | Immunization with inactivated measles virus vaccine: effect of booster dose and response to natural challenge | |
| Popow‐Kraupp et al. | A controlled trial for evaluating two live attenuated mumps‐measles vaccines (Urabe Am 9‐Schwarz and Jeryl Lynn‐Moraten) in young children | |
| Chadha et al. | Ten-year serological follow up of hepatitis B vaccine recipients | |
| Flehmig et al. | Early appearance of neutralizing antibodies after vaccination with an inactivated hepatitis A vaccine |